What the FDA labels say about taking them together
Atropine and irinotecan
Irinotecan's FDA label of May 12, 2026 names atropine in its boxed warning section; the atropine labels PlainMeds reads (4) do not name irinotecan. The irinotecan label: “Administer atropine, if not contraindicated, for early diarrhea of any severity.”
Check it at the source: the atropine FDA label on DailyMed (effective May 18, 2026, Hospira, Inc.); the irinotecan FDA label on DailyMed (effective May 12, 2026, Pharmacia & Upjohn Company LLC).
What does the atropine label say about irinotecan?
Atropine's label (effective May 18, 2026) and its 3 other brand-application labels do not name irinotecan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Atropine Sulfate), Hospira, Inc., effective May 18, 2026 (SPL set ad8916e7-206e-409e-2582-30d072845dd4), via openFDA; the full label on DailyMed
What does the irinotecan label say about atropine?
Irinotecan label, boxed warningEarly diarrhea may be accompanied by cholinergic symptoms which may be prevented or ameliorated by atropine.
Irinotecan label, warnings and precautionsConsider prophylactic or therapeutic administration of 0.25 mg to 1 mg of intravenous or subcutaneous atropine (unless clinically contraindicated).
Onivyde label (Ipsen Biopharmaceuticals, Inc., March 3, 2025), boxed warningAdminister atropine, if not contraindicated, for early diarrhea of any severity [see Dosage and Administration (2.2) and Warnings and Precautions (5.2) ].
Onivyde label (Ipsen Biopharmaceuticals, Inc., March 3, 2025), warnings and precautionsAdminister intravenous or subcutaneous atropine 0.25 to 1 mg (unless clinically contraindicated) for early onset diarrhea of any severity.
Source: FDA drug label (Onivyde, NDA207793), Ipsen Biopharmaceuticals, Inc., effective March 3, 2025 (SPL set c8b58efa-1820-48a4-b70d-62918fc4abfc), via openFDA
Source: FDA drug label (Camptosar), NDA020571 (Pfizer Inc), as published by Pharmacia & Upjohn Company LLC, effective May 12, 2026 (SPL set e518dfc6-7e93-4fee-a66c-51e1ab71c056), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Atropine | Irinotecan | |
|---|---|---|
| Labeled for | n/a | Colorectal cancer |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $7.74 per mL 1% eye drops | n/a |
| Shortage now | In shortage | A presentation being discontinued |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once